Isoray Completes Merger with Viewpoint Molecular Targeting

IBA Acquires ORA Group to Expand Nuclear Medicine Capabilities

December 19, 2025

Medical Devices

Ion Beam Applications S.A. (IBA) has acquired ORA Group (ORA - Optimized Radiochemical Applications SRL and OOC) to strengthen its leadership in nuclear medicine and radiochemistry. The cash-free, debt-free transaction (total consideration €15–20 million) is financed from IBA’s own funds and existing credit facilities and is immediately accretive to IBA Technologies’ revenue and EBITDA; ORA founder Vincent Tadino will continue with the combined business as CTO.

Tenpoint Therapeutics and Visus Therapeutics Complete Merger to Advance Ophthalmic Pipeline

December 12, 2024

Biotechnology

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. completed a merger to combine their ophthalmic drug development programs, bringing the late-stage presbyopia candidate BRIMOCHOL PF together with Tenpoint’s broader aging-eye pipeline. The combined company is launching a crossover financing round with participation from institutional investors to support an NDA filing and a planned US commercial launch of BRIMOCHOL PF in the 1H of 2026. Henric Bjarke was named CEO of the merged company.

Bristol Myers Squibb Acquires RayzeBio in $4.1B Deal

December 26, 2023

Biotechnology

Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in an all-cash transaction, valuing the equity at approximately $4.1 billion. The deal is expected to close in the first half of 2024, subject to customary conditions, bringing RayzeBio’s actinium-based radiopharmaceutical platform and clinical pipeline into BMS’s oncology franchise.

Novartis Acquires Mariana Oncology

May 2, 2024

Biotechnology

Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments, bringing Mariana's peptide-based radiopharmaceutical pipeline and manufacturing capabilities into Novartis. The deal adds radioligand therapeutic discovery, isotope supply chain and manufacturing know-how to Novartis to accelerate development and commercialization of targeted cancer therapies.

Bruker Corporation Acquires Canopy Biosciences, LLC

September 11, 2020

Biotechnology

Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.

Continuity Biosciences Acquires Focal Medical

June 4, 2025

Biotechnology

Continuity Biosciences, LLC has acquired Focal Medical, Inc., a North Carolina–based biopharmaceutical company developing iontophoresis-based, site-specific chemotherapy delivery for pancreatic cancer. The acquisition transfers Focal Medical's patent estate, device platform, equipment, licensing agreements and key personnel to Continuity as it expands its drug‑delivery and device-enabled therapeutics capabilities and advances the lead program toward clinical trials.